What is CytoDyn?
CytoDyn Inc. is a publicly traded, clinical-stage biotechnology firm based in Vancouver, Washington, established in 2002. The company is dedicated to pioneering novel treatments for severe diseases, with a primary focus on oncology and immunology. Its lead candidate, leronlimab, is a humanized monoclonal antibody designed to target the CCR5 receptor, a critical regulator of immune responses implicated in cancer, inflammation, and certain infectious diseases. Leronlimab is currently undergoing investigation for a range of indications, notably in solid-tumor oncology, including metastatic colorectal cancer and triple-negative breast cancer.
How much funding has CytoDyn raised?
CytoDyn has raised a total of $73.2M across 6 funding rounds:
Debt
$1.1M
Share Placement
$12M
Debt
$15M
Debt
$2.5M
Debt
$25M
Unspecified
$17.5M
Debt (2017): $1.2M, investors not publicly disclosed
Share Placement (2019): $12M led by Undisclosed
Debt (2020): $15M, investors not publicly disclosed
Debt (2020): $2.5M, investors not publicly disclosed
Debt (2021): $25M, investors not publicly disclosed
Unspecified (2026): $17.5M, investors not publicly disclosed
What's next for CytoDyn?
The recent major strategic investment signals a pivotal moment for CytoDyn, likely enabling the acceleration of its clinical trial programs and the expansion of its research and development efforts. This capital infusion is expected to support the advancement of leronlimab through late-stage trials and toward potential commercialization, positioning CytoDyn to address significant unmet needs in cancer and immunology. The company's trajectory suggests a focus on scaling operations and solidifying its market presence within the competitive biotechnology landscape.
See full CytoDyn company page
